Literature DB >> 7730477

Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b.

A E Agbarakwe1, H Griffiths, N Begg, H M Chapel.   

Abstract

AIM: To investigate the avidity of specific IgG polyribosyl ribitol phosphate (PRP) antibodies induced by three Haemophilus influenzae type b (Hib) conjugate vaccines: PRP-meningococcal outer membrane protein complex (PRP-OMP), PRP-non-toxic mutant diphtheria toxin, CRM197 (HbOC) and PRP-tetanus toxoid (PRP-T).
METHODS: One hundred and ten infants were immunised with one of the vaccines at two, three and four months of age. Blood samples were taken after each vaccination and serum stored at -20 degrees C. Serum samples collected after the third course (that is, at five months of age) were submitted to antibody avidity assessment, using a urea enzyme linked immunosorbent assay (ELISA).
RESULTS: All three conjugate vaccines elicited IgG PRP antibodies of high median avidity. The resultant antibody populations were heterogeneous with regard to avidity, which in turn was independent of PRP antibody concentration.
CONCLUSIONS: With the recent findings of a correlation between bactericidal killing and affinity, our data highlight the need for a protective level to be expressed qualitatively as well as quantitatively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730477      PMCID: PMC502440          DOI: 10.1136/jcp.48.3.206

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.

Authors:  B A Claesson; B Trollfors; T Lagergard; J Taranger; D Bryla; G Otterman; T Cramton; Y Yang; C B Reimer; J B Robbins
Journal:  J Pediatr       Date:  1988-05       Impact factor: 4.406

2.  Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate.

Authors:  B A Claesson; R Schneerson; J B Robbins; J Johansson; T Lagergard; J Taranger; D Bryla; L Levi; T Cramton; B Trollfors
Journal:  J Pediatr       Date:  1989-01       Impact factor: 4.406

3.  A major crossreactive idiotype associated with human antibodies to the Haemophilus influenzae b polysaccharide. Expression in relation to age and immunoglobulin G subclass.

Authors:  A H Lucas; D M Granoff
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  Haemophilus influenzae type b disease in the Oxford region.

Authors:  G Tudor-Williams; J Frankland; D Isaacs; R T Mayon-White; J A MacFarlane; M P Slack; E Anderson; D G Rees; E R Moxon
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

5.  Immunogenicity of Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine.

Authors:  D M Granoff; A Chacko; K R Lottenbach; K E Sheetz
Journal:  J Pediatr       Date:  1989-06       Impact factor: 4.406

6.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  P Anderson
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

7.  Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine.

Authors:  J Eskola; H Käyhty; H Peltola; V Karanko; P H Mäkelä; J Samuelson; L K Gordon
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

8.  Class-specific antibody response to Haemophilus influenzae type b capsular polysaccharide vaccine.

Authors:  H Käyhty; R Schneerson; A Sutton
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

9.  Recent primary toxoplasma infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; M Lappalainen; I Seppäiä; O Mäkelä
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

10.  Anti-DNA antibodies: problems in their study and interpretation.

Authors:  D Eilat
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

View more
  5 in total

1.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

2.  Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.

Authors:  James T Gaensbauer; Jeremy T Rakhola; Carolyne Onyango-Makumbi; Michael Mubiru; Jamie E Westcott; Nancy F Krebs; Edwin J Asturias; Mary Glenn Fowler; Elizabeth McFarland; Edward N Janoff
Journal:  Clin Vaccine Immunol       Date:  2014-10-08

3.  Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection.

Authors:  M Narita; S Yamada; Y Matsuzono; O Itakura; T Togashi; H Kikuta
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

4.  Immunoglobulin G avidities in infants in Mexico after primary immunization with three doses of polyribosylribitol phosphate-tetanus toxoid Haemophilus influenzae type b vaccine.

Authors:  Patricia Gómez-de-León; F Javier Díaz-García; Alberto Villaseñor-Sierra; Jorge Segura; Martha I Carranza; José Luis Arredondo-Garcia; José Ignacio Santos
Journal:  Clin Vaccine Immunol       Date:  2008-04-16

5.  Specific antibodies against vaccine-preventable infections: a mother-infant cohort study.

Authors:  Christine Jones; Louisa Pollock; Sara M Barnett; Anna Battersby; Beate Kampmann
Journal:  BMJ Open       Date:  2013-04-11       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.